Rob Louie, RPh, MBA

“RemedyOne’s talented team has decades of experience in the health care delivery system and is committed to fixing inefficiencies in the healthcare system. We take the time to listen to our client’s unique situations in order to provide innovative solutions tailored to the individual needs of our clients.”

Study Shows Talarozole May Help Osteoarthritis Patients

Healthline recently asked me to provide context for an article about recent research showing that talarozole may reduce and modify the symptoms of osteoarthritis, a condition that impacts more than 32 million American adults. Talarozole was developed in the early 2000s and is currently not licensed or approved to treat any condition. A team at

Study Shows Talarozole May Help Osteoarthritis Patients Read More »

It’s Been a Long Time Coming for Long-Term Topical Psoriasis Treatments

RemedyOne EVP of clinical services Robert Louie recently published an article for Pharmaphorum about topical psoriasis treatments Vtama and Zoryve. Below is an excerpt.  Psoriasis is a tricky disease to manage, as drawbacks and side effects loom with each and every type of treatment. Anyone who watches television has heard the list of potential adverse

It’s Been a Long Time Coming for Long-Term Topical Psoriasis Treatments Read More »

Relyvrio and the ALS Treatment Landscape

Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s Disease, is a rare, progressive, neurodegenerative disorder that affects nerve cells in the spinal cord and the brain. These motor neurons govern voluntary movement and muscle control. ALS causes motor neurons to degenerate and eventually die, resulting in muscle weakness, disability and eventually death. The

Relyvrio and the ALS Treatment Landscape Read More »

Enhertu: The New Oncology ‘Smart Bomb’

An article on Health.com recently quoted me about an exciting new FDA-approved drug shown to extend metastatic breast cancer patients’ lives significantly. Enhertu is a combination of two known therapies, trastuzumab and deruxtecan work in tandem to target the lower levels of HER2 proteins present.   As I described in the article, these two therapies work

Enhertu: The New Oncology ‘Smart Bomb’ Read More »

New Developments in Macular Degeneration/Diabetic Eye Disease

Visual impairment can be a major health issue for older adults, ranging from a minor inconvenience to vision loss significantly impacting quality of life.  Age-related macular degeneration (AMD) is a neurodegenerative disease of the retina and would fall into the latter category. It’s the leading cause of irreversible vision loss among the elderly. In 2016,

New Developments in Macular Degeneration/Diabetic Eye Disease Read More »

No One Really Knows How We’ll Pay for Gene Therapies

Gene therapies are here and they have the potential to be miraculous. And extremely expensive. The science behind these therapies are truly the realization of a sci-fi promise — that science can alter genes in a cell to eliminate a disease. The price tags — upwards of $2 million per patient — feel like something out

No One Really Knows How We’ll Pay for Gene Therapies Read More »

Biogen’s New Alzheimer’s Drug is a Compound of Hope and Controversy

For the first time in 18 years, the FDA has approved a drug to treat patients with Alzheimer’s disease. It’s great news for the millions of Americans, and their family members, who are fighting this terrible disease. But all the news was not great. The approval did not come without controversy. The fact that three

Biogen’s New Alzheimer’s Drug is a Compound of Hope and Controversy Read More »